How to Get Jatenzo in New Jersey

Who Can Prescribe Jatenzo in New Jersey

Any physician (MD or DO) licensed in New Jersey can prescribe Jatenzo for diagnosed male hypogonadism. Nurse practitioners hold full practice authority in New Jersey after a supervised transition period, meaning experienced NPs can independently prescribe Schedule III controlled substances like testosterone undecanoate [1]. Physician assistants may prescribe under a collaborative agreement with a supervising physician.

Endocrinologists and urologists write the majority of testosterone prescriptions nationally, but primary care physicians and men's health specialists also prescribe Jatenzo regularly. The Endocrine Society's 2018 clinical practice guideline recommends that any clinician diagnosing hypogonadism confirm the condition with at least two morning serum total testosterone measurements taken on separate days [2]. New Jersey does not impose additional state-level restrictions beyond federal DEA Schedule III requirements.

For patients who prefer remote care, New Jersey permits synchronous audio-video telehealth visits for controlled substance prescribing. The state's telemedicine laws, updated in 2020, allow out-of-state physicians to treat NJ patients if they hold a New Jersey telemedicine permit or a full NJ medical license. This means a board-certified endocrinologist in another state can evaluate, diagnose, and prescribe Jatenzo to a patient sitting in Newark or Cherry Hill, provided the clinician meets NJ licensing standards.

Required Labs Before Starting Jatenzo

A Jatenzo prescription requires documented biochemical evidence of testosterone deficiency. The minimum lab workup includes two fasting morning total testosterone levels drawn before 10:00 AM on separate days, each falling below 300 ng/dL [2].

Most prescribers in New Jersey also order a broader panel before initiating therapy. The Endocrine Society guideline recommends baseline complete blood count (CBC) with hematocrit, a fasting lipid panel, hepatic function tests, and prostate-specific antigen (PSA) for men over 40 [2]. Because Jatenzo carries an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) related to cardiovascular risk, the prescribing information also calls for blood pressure monitoring at baseline and during dose titration [1].

Swerdloff et al. published key trial data in the Journal of Clinical Endocrinology & Metabolism (2020) showing that oral testosterone undecanoate (the active compound in Jatenzo) restored eugonadal testosterone levels in 87% of hypogonadal men at 52 weeks. Mean testosterone concentration reached 489 ng/dL at the 237 mg twice-daily dose. Hematocrit elevations above 54% occurred in 3.3% of participants, reinforcing why CBC monitoring matters [3].

Labs can be drawn at any Quest Diagnostics or LabCorp location across New Jersey, both of which have dozens of draw sites in the state. Many telehealth TRT platforms partner directly with these networks and can send lab orders electronically before the first video consultation. Some patients arrive at their initial visit with labs already in hand. That shortens the path to a prescription significantly.

The Telehealth Pathway: Step by Step

Getting Jatenzo through a telehealth provider in New Jersey follows a predictable sequence. The entire process, from first click to capsules in hand, typically takes 7 to 21 days.

Step 1: Lab work. The provider sends a lab requisition to a local draw site. You complete fasting blood work before 10:00 AM. Results return in 1 to 3 business days.

Step 2: Video consultation. A licensed prescriber reviews your labs, symptoms, medical history, and treatment goals over a synchronous video call. New Jersey law requires this to be a live audio-video interaction for initial controlled substance prescriptions. Phone-only visits do not qualify for first-time Schedule III prescribing.

Step 3: Diagnosis and prescription. If labs confirm total testosterone below 300 ng/dL on two separate draws and clinical symptoms align, the provider documents a diagnosis of male hypogonadism (ICD-10: E29.1) and writes a Jatenzo prescription.

Step 4: Prior authorization (if needed). The provider's team submits PA paperwork to your insurer. Turnaround ranges from 24 hours to 14 business days depending on the payer.

Step 5: Pharmacy fulfillment. The prescription routes to a retail, specialty, or mail-order pharmacy. You receive your Jatenzo capsules.

New Jersey's telehealth infrastructure is mature. The state processed over 12 million telehealth claims in the two years following its 2020 telemedicine parity law, according to data from the NJ Department of Banking and Insurance. That regulatory environment makes it straightforward for men across the state to access testosterone therapy without driving to an in-person clinic.

Pharmacy Options in New Jersey

Jatenzo is a branded product stocked at most large retail pharmacies, including CVS, Walgreens, and Rite Aid locations throughout New Jersey. Specialty pharmacies like Alto, Capsule, and Optum Specialty also dispense the drug and may offer home delivery within the state.

New Jersey licenses 503A compounding pharmacies that can prepare oral testosterone undecanoate capsules as a compounded alternative. Compounded versions are not Jatenzo (they lack the brand's specific lipid-based formulation and REMS enrollment), but they offer a lower-cost option for patients who cannot afford the brand or whose insurance denies coverage. The New Jersey State Board of Pharmacy oversees 503A facilities, which must compound pursuant to a valid patient-specific prescription.

Price varies sharply between brand Jatenzo and compounded oral TU. Brand Jatenzo carries a wholesale acquisition cost above $700 per month without insurance. Tolmar offers a manufacturer copay card that can reduce out-of-pocket costs to as little as $0 for commercially insured patients [4]. Compounded oral testosterone undecanoate from a 503A pharmacy typically runs $80 to $200 per month, depending on the pharmacy and dose.

Patients filling at a retail pharmacy should confirm the location stocks Jatenzo before the prescription is sent, because not all pharmacies keep oral testosterone undecanoate on the shelf. A quick call saves a trip. Specialty and mail-order pharmacies generally maintain consistent inventory.

Insurance and Prior Authorization in New Jersey

New Jersey Medicaid covers Jatenzo for the indication of male hypogonadism, but requires prior authorization [5]. Commercial insurers in the state, including Horizon Blue Cross Blue Shield (the state's dominant carrier), Aetna, Cigna, and UnitedHealthcare, each maintain their own PA criteria. The common thread across payers: documentation of two low testosterone levels, clinical symptoms, and a trial or documented contraindication to injectable testosterone (typically cited as the first-line, lower-cost option).

Prior authorization submissions for Jatenzo in New Jersey generally require the following documentation:

• Two morning total testosterone levels below 300 ng/dL on separate days
• Clinical symptoms of hypogonadism (fatigue, decreased libido, erectile dysfunction, loss of muscle mass)
• Reason injectable testosterone is not appropriate (needle phobia, inability to self-inject, history of polycythemia on injectables, patient preference with clinical justification)
• Prescriber's NPI number and practice address
• ICD-10 diagnosis code (E29.1 for testicular hypofunction)

The American Urological Association's 2018 guideline on testosterone deficiency notes that oral formulations provide a valid alternative for men who cannot or will not use injectable preparations [6]. Citing this guideline in a PA letter strengthens the medical necessity argument. The FDA approved Jatenzo in March 2019 specifically as an oral option for men with hypogonadism who need testosterone replacement but want to avoid injections [4].

Turnaround on NJ Medicaid PA decisions is typically 3 to 5 business days. Commercial plans vary. Horizon BCBSNJ publishes a 15-business-day standard for non-urgent requests. An expedited or urgent PA, when clinically justified, must be decided within 72 hours under NJ insurance regulations.

If a PA is denied, New Jersey patients have the right to appeal. The state's Independent Health Care Appeals Program provides an external review mechanism for disputed denials. Your prescriber's office can initiate a peer-to-peer review with the insurer's medical director, which resolves many denials before a formal appeal becomes necessary.

Dose Titration and Monitoring After Starting Jatenzo

Jatenzo dosing starts at 237 mg taken orally twice daily with food. The FDA label specifies that the capsules must be swallowed whole (not chewed or opened) and taken with a meal containing fat to ensure adequate absorption [4]. After approximately one month, a follow-up serum testosterone level is drawn 4 to 6 hours after the morning dose. Based on that level, the prescriber adjusts the dose.

Three dose strengths exist: 158 mg, 198 mg, and 237 mg. The target is a steady-state testosterone concentration between 300 and 1,050 ng/dL. In the Swerdloff et al. trial, 87% of men achieved this range at 52 weeks, with the majority maintained on the 237 mg or 198 mg twice-daily dose [3].

Monitoring intervals recommended by the Endocrine Society are as follows [2]:

• Month 1: Serum testosterone, blood pressure check
• Month 3: Testosterone, CBC with hematocrit, hepatic panel
• Months 6 and 12: Testosterone, CBC, lipid panel, PSA (if over 40)
• Annually thereafter: Same panel, plus bone density if indicated

Hematocrit above 54% triggers a dose reduction or temporary hold. The Jatenzo REMS program specifically mandates cardiovascular risk counseling and periodic blood pressure monitoring because the FDA label carries a boxed warning regarding major adverse cardiovascular events [4]. New Jersey prescribers, whether in-person or via telehealth, are responsible for REMS enrollment before dispensing.

One practical advantage of oral testosterone over injections: steady serum levels. Injectable testosterone cypionate produces peak-trough fluctuations, with testosterone spiking 48 to 72 hours post-injection and falling toward baseline before the next dose. Oral testosterone undecanoate produces more stable day-to-day levels when taken consistently twice daily with food [3]. Patients who experienced mood swings or energy crashes on injectables sometimes report fewer of these symptoms after switching to Jatenzo.

Transferring a Jatenzo Prescription to New Jersey

If you're moving to New Jersey from another state and already have an active Jatenzo prescription, the transfer process depends on your prescriber's licensure. A physician licensed only in your previous state cannot continue prescribing to you once you establish residency in NJ. You will need either a new NJ-licensed prescriber or a telehealth provider who holds a New Jersey license.

Your existing lab results remain valid. New Jersey prescribers accept out-of-state lab work as long as the draw dates, values, and CLIA-certified lab identifiers are documented. You do not need to repeat qualifying testosterone levels unless your prescriber requests updated values for clinical reasons.

For the pharmacy transfer itself, New Jersey pharmacies can accept prescriptions transferred from out-of-state pharmacies for controlled substances under DEA regulations. The sending and receiving pharmacists coordinate the transfer directly. Allow 1 to 3 business days for processing.

Insurance may be the larger variable. If your plan changes with the move, a new prior authorization will likely be required under your New Jersey-based insurer. Bring copies of your previous PA approval letter, lab results, and prescriber notes to simplify the new submission.

Cardiovascular Considerations and the REMS Program

The FDA approved Jatenzo with a REMS due to observed increases in systolic blood pressure during clinical trials. In the key study, mean systolic blood pressure increased by 3 to 5 mmHg compared to baseline, and 7.4% of men on the 237 mg dose developed new-onset hypertension [3]. The boxed warning states that Jatenzo can cause blood pressure increases and increase the risk of major adverse cardiovascular events.

A 2023 study published in The New England Journal of Medicine (the TRAVERSE trial, N=5,246) examined cardiovascular safety of testosterone therapy broadly. The trial found that testosterone replacement did not significantly increase the incidence of major adverse cardiovascular events compared to placebo in hypogonadal men aged 45 to 80 with pre-existing cardiovascular disease or high cardiovascular risk (hazard ratio 0.99, 95% CI 0.81 to 1.21) [7]. While TRAVERSE used a transdermal gel rather than oral testosterone undecanoate, the findings provided reassurance about testosterone replacement therapy as a class.

New Jersey prescribers are expected to counsel patients on cardiovascular risk factors, monitor blood pressure at each follow-up, and document REMS compliance in the medical record. The American Heart Association recommends that men starting testosterone therapy have a baseline cardiovascular risk assessment, including blood pressure, lipid panel, and fasting glucose [8].